Arcturus Therapeutics Holdings Inc (ARCT, Financial), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider transaction. According to a recent SEC filing, Chief Scientific Officer & COO Pad Chivukula sold 17,435 shares of the company on March 25, 2024.
Over the past year, the insider has sold a total of 111,000 shares and has not made any purchases of the company's stock. This latest transaction continues a pattern of insider sales at Arcturus Therapeutics Holdings Inc, with a total of 13 insider sells and no insider buys occurring over the same timeframe.
On the day of the sale, shares of Arcturus Therapeutics Holdings Inc were trading at $35.02, valuing the company at a market cap of $883.627 million.
The stock's price-to-GF-Value ratio stands at 0.31, with a GuruFocus Value of $111.54, indicating that the stock is considered a Possible Value Trap, Think Twice according to its GF Value. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated based on historical trading multiples, a GuruFocus adjustment factor related to the company's past performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
